Featured Research

from universities, journals, and other organizations

Experimental Drug Shows Promise In Advanced Kidney Cancer

Date:
September 28, 2007
Source:
European Cancer Conference
Summary:
A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumor fails to respond to the cutting edge therapy. The study showed that the experimental drug, axitinib, shrank tumors and delayed progression of the disease in a group of patients who are among the toughest to treat.

A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour fails to respond to the cutting edge therapy.

Related Articles


The study, presented September 26 at the European Cancer Conference in Barcelona, showed that the experimental drug, axitinib, shrank tumours and delayed progression of the disease in a group of patients who are among the toughest to treat.

In the study, scientists gave axitinib to 62 patients whose kidney cancer had spread and who had not benefited from a standard treatment, sorafenib, a targeted therapy designed to disrupt cell division signals in cancer cells and block the tumour’s ability to form new blood vessels that help it grow. Fourteen of the patients also had been given – to no avail – another similarly targeted drug, sunitinib, after the sorafenib had failed to work. Axitinib works similarly to the other two but is believed to be more potent.

“More than half the patients – 51 percent – experienced tumour shrinkage and in 23 percent of them the shrinkage is considered significant,” said lead investigator Dr Brian I. Rini, an associate professor of medicine at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, USA, and a paid member of the Pfizer scientific advisory board. “Preliminary analysis shows the progression-free survival was on average more than 7.7 months. We think these results are impressive because these patients were heavily pre-treated and with drugs thought to be similar to axitinib.

“The disease progressed in only 24 percent of patients, which we think is low in this kind of setting,” Rini added. The study found the tumour remained stable in 37 percent of the patients.

“Historically, metastatic kidney cancer has been very tough to treat, with a median survival of 12 months. Through the results of this trial, it appears that axitinib is a very active drug in renal cell cancer that can benefit a large number of patients,” Rini added.

The drug’s maker, Pfizer, paid for the study. Axitinib is also being tested in advanced pancreatic, thyroid, lung and breast cancers.


Story Source:

The above story is based on materials provided by European Cancer Conference. Note: Materials may be edited for content and length.


Cite This Page:

European Cancer Conference. "Experimental Drug Shows Promise In Advanced Kidney Cancer." ScienceDaily. ScienceDaily, 28 September 2007. <www.sciencedaily.com/releases/2007/09/070926100542.htm>.
European Cancer Conference. (2007, September 28). Experimental Drug Shows Promise In Advanced Kidney Cancer. ScienceDaily. Retrieved December 22, 2014 from www.sciencedaily.com/releases/2007/09/070926100542.htm
European Cancer Conference. "Experimental Drug Shows Promise In Advanced Kidney Cancer." ScienceDaily. www.sciencedaily.com/releases/2007/09/070926100542.htm (accessed December 22, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, December 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Christmas Kissing Good for Health

Christmas Kissing Good for Health

Reuters - Innovations Video Online (Dec. 22, 2014) Scientists in Amsterdam say couples transfer tens of millions of microbes when they kiss, encouraging healthy exposure to bacteria. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Brain-Dwelling Tapeworm Reveals Genetic Secrets

Brain-Dwelling Tapeworm Reveals Genetic Secrets

Reuters - Innovations Video Online (Dec. 22, 2014) Cambridge scientists have unravelled the genetic code of a rare tapeworm that lived inside a patient's brain for at least four year. Researchers hope it will present new opportunities to diagnose and treat this invasive parasite. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Touch-Free Smart Phone Empowers Mobility-Impaired

Touch-Free Smart Phone Empowers Mobility-Impaired

Reuters - Innovations Video Online (Dec. 21, 2014) A touch-free phone developed in Israel enables the mobility-impaired to operate smart phones with just a movement of the head. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Earthworms Provide Cancer-Fighting Bacteria

Earthworms Provide Cancer-Fighting Bacteria

Reuters - Innovations Video Online (Dec. 21, 2014) Polish scientists isolate bacteria from earthworm intestines which they say may be used in antibiotics and cancer treatments. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins